Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/13852
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVigorito, Afonso Celso-
dc.contributor.authorApperley, Jane-
dc.contributor.authorFlowers, Mary Evelyn Dantas-
dc.contributor.authorBesien, Koen Van-
dc.contributor.authorElmaagacli, Ahmet-
dc.contributor.authorGrigg, Andrew-
dc.contributor.authorReddy, Vijay-
dc.contributor.authorBacigalupo, Andrea-
dc.contributor.authorKolb, Hans-Jochem-
dc.contributor.authorBouzas, Luis Fernando da Silva-
dc.contributor.authorMichallet, Mauricette-
dc.contributor.authorPrince, Henry Miles-
dc.contributor.authorKnobler, Robert-
dc.contributor.authorParenti, Dennis-
dc.contributor.authorGallo, Jose-
dc.contributor.authorGreinix, Hildegard Theresia-
dc.date.accessioned2023-05-22T13:56:18Z-
dc.date.available2023-05-22T13:56:18Z-
dc.date.issued2008-10-
dc.identifier.issn1528-0020-
dc.identifier.urihttps://ninho.inca.gov.br/jspui/handle/123456789/13852-
dc.description.abstractChronic graft-versus-host disease (cGVHD) is a major limitation of successful hematopoietic cell transplantation. The safety and efficacy of extracorporeal photopheresis (ECP) for 12 to 24 weeks together with standard therapy was compared with standard therapy alone in patients with cutaneous manifestations of cGVHD that could not be adequately controlled by corticosteroid treatment. The primary efficacy end point was a blinded quantitative comparison of percent change from baseline in Total Skin Score (TSS) of 10 body regions at week 12. Ninety-five patients were randomized to either ECP and standard therapy (n = 48) or standard therapy alone (n = 47). The median percentage improvement in TSS at week 12 was 14.5% for the ECP arm and 8.5% for the control arm (P = .48). The proportion of patients who had at least a 50% reduction in steroid dose and at least a 25% decrease from baseline in TSS was 8.3% in the ECP arm at week 12 and 0% in the control arm (P = .04). The nonblinded investigator assessment of skin complete or partial responses revealed a significant improvement in favor of ECP (P < .001). ECP was generally well tolerated. These results suggest that ECP may have a steroid-sparing effect in the treatment of cGVHDpt_BR
dc.subjectDoença Crônicapt_BR
dc.subjectChronic Diseasept_BR
dc.subjectEnsaio Clínico Fase IIpt_BR
dc.subjectClinical Trial Phase IIpt_BR
dc.subjectEnsaios Clínicos Controlados não Aleatórios como Assuntopt_BR
dc.subjectNon-Randomized Controlled Trials as Topicpt_BR
dc.subjectFotoferesept_BR
dc.subjectPhotopheresispt_BR
dc.subjectEstudo Multicêntricopt_BR
dc.subjectMulticenter Studypt_BR
dc.subjectDoença Enxerto-Hospedeiropt_BR
dc.subjectGraft vs Host Diseasept_BR
dc.titleA multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host diseasept_BR
dc.TypeArticlept_BR
Appears in Collections:Hospital do Câncer I (HCI)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.